Dr. Lane joined Cincinnati Children's in July 2013. He has published novel statistical methods in the areas of adaptive and optimal experimental designs with applications to phase I and phase II clinical trials. As a graduate student he received funding from the NIH to spend the fall semester of 2011 at the University of Cambridge in the Isaac Newton Institute for Mathematical Sciences. He has also received NSF travel awards to present his research at national and international conferences.
Clinical trials; survival analysis; structural equation modeling
Experimental Hematology and Cancer Biology, Cancer and Blood Diseases
Efficiency of observed information adaptive designs in linear models. Journal of Statistical Planning and Inference. 2023; 223:63-74.
Conditional information and inference in response-adaptive allocation designs. Statistics in Medicine. 2022; 41:390-406.
Adaptive Designs for Optimal Observed Fisher Information. Journal of the Royal Statistical Society: Series B (Statistical Methodology). 2020; 82:1029-1058.
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. The New England Journal of Medicine. 2020; 382:2524-2533.
Graphical data mining of cancer mechanisms with SEMA. Bioinformatics. 2019; 35:4413-4418.
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. The New England Journal of Medicine. 2019; 380:121-131.
A comparative survey of functional footprints of EGFR pathway mutations in human cancers. Oncogene: Including Oncogene Reviews. 2014; 33:5078-5089.
Information in a two-stage adaptive optimal design. Journal of Statistical Planning and Inference. 2014; 144:173-187.
Two-Stage Adaptive Optimal Design with Fixed First-Stage Sample Size. Journal of Probability and Statistics. 2012; 2012:1-15.
Adam Lane, PhD, Russell E. Ware, MD, PhD3/22/2021